Ali Noman, Patel Peysh, Wahab Ali, Das Arka, Blackman Daniel J, Cunnington Michael S, Malkin Christopher J
Department of Cardiology, Leeds General Infirmary, Leeds, UK.
J Cardiovasc Med (Hagerstown). 2021 Feb 1;22(2):126-132. doi: 10.2459/JCM.0000000000001112.
We compared strategies in the treatment of decompensated severe aortic stenosis. The hypothesis was that undertaking urgent or emergency transcatheter aortic valve implantation (TAVI) directly in such patients is safer and more effective than urgent or emergency balloon aortic valvuloplasty (BAV) followed by elective TAVI or surgical aortic valve replacement (SAVR).
This was a single-centre retrospective study including all consecutive patients who underwent urgent or emergency BAV or TAVI for decompensated severe aortic stenosis between September 2014 and February 2018. Primary endpoints were 30-day and 1-year mortality.
Fifty-two patients underwent urgent or emergency BAV and 87 underwent TAVI. Baseline characteristics of the two groups were well matched. Significant differences were noted between the two groups in 30-day all-cause mortality (88.5% BAV patients alive at 30 days, 97.7% TAVI patients; P < 0.05) and 1-year all-cause mortality (44.2% BAV patients alive at 1 year, 88.5% TAVI patients; P < 0.001). At 1 year, the estimated hazard ratio for patients undergoing BAV was 11.2 (95% confidence interval: 4.67-26.9; P < 0.001) when adjusted for potential confounding variables. Patients in the BAV group who successfully underwent subsequent TAVI or SAVR all survived for 365 days, but there was no significant 1-year mortality difference compared with those who underwent urgent or emergency TAVI (100 vs. 88.5%; P > 0.155).
Our results suggest treatment of decompensated severe aortic stenosis with urgent or emergency TAVI may be associated with improved survival outcomes when compared with a strategy of performing BAV as a bridge to subsequent TAVI or SAVR.
我们比较了失代偿性重度主动脉瓣狭窄的治疗策略。我们的假设是,对此类患者直接进行紧急或急诊经导管主动脉瓣植入术(TAVI)比先进行紧急或急诊球囊主动脉瓣成形术(BAV),然后择期进行TAVI或外科主动脉瓣置换术(SAVR)更安全、更有效。
这是一项单中心回顾性研究,纳入了2014年9月至2018年2月期间因失代偿性重度主动脉瓣狭窄接受紧急或急诊BAV或TAVI的所有连续患者。主要终点是30天和1年死亡率。
52例患者接受了紧急或急诊BAV,87例接受了TAVI。两组的基线特征匹配良好。两组在30天全因死亡率(30天时88.5%的BAV患者存活,97.7%的TAVI患者存活;P<0.05)和1年全因死亡率(1年时44.2%的BAV患者存活,88.5%的TAVI患者存活;P<0.001)方面存在显著差异。在调整潜在混杂变量后,1年时,接受BAV的患者的估计风险比为11.2(95%置信区间:4.67-26.9;P<0.001)。成功接受后续TAVI或SAVR的BAV组患者均存活365天,但与接受紧急或急诊TAVI的患者相比,1年死亡率无显著差异(100%对88.5%;P>0.155)。
我们的结果表明,与将BAV作为后续TAVI或SAVR的桥梁的策略相比,采用紧急或急诊TAVI治疗失代偿性重度主动脉瓣狭窄可能会改善生存结局。